52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Onkure And Pfizer Enter Agreement To Evaluate Combination Of Oki-179 And Binimetinib
EMD Sereno Says Bavencio Pivotal Phase III Javelin Bladder 100 Results Published In The New England Journal Of Medicine
Pfizer Sees $18 - $20 Bln Lost Revenue Due To Exclusivity Losses Beginning In 2026 - Investor Day
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Biotechnology & Drugs
235 E 42ND ST
NEW YORK, NY
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Group President, Pfizer Biopharmaceuticals Group
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Food and Drug Administration is expected to soon announce new, more stringent standards for an emergency authorization of a COVID-19 vaccine, lowering the chances that one might be cleared for use before the Nov. 3 election, the Washington Post reported on Tuesday.
(Updates Moderna, adds Beijing Wantai Biological Pharmacy, COVAXX, University Hospital Tuebingen, China's Institute of Biotechnology) Sept 21 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human...
U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.
Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run.
* BioNTech CEO: Request for approval likely late-Oct, early-Nov
Pfizer Inc said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
Pfizer Inc said on Tuesday patients were showing mild-to-moderate tolerability to either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
* UK parliament to vote on plan to break Brexit divorce treaty
Pfizer Inc said on Monday that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.
Pfizer Inc and BioNTech SE on Saturday proposed to the U.S Food and Drug Administration (FDA) to expand their Phase 3 pivotal COVID-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
Pfizer Inc and BioNTech SE have proposed to the U.S Food and Drug Administration (FDA) to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to about 44,000 participants, the companies said on Saturday.
Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.
* Merck, Pfizer pledge to skirt politics, follow data (Adds details about Merck vaccine plans, comments from Pfizer CEO)
U.S. drugmaker Pfizer said it should know by the end of October whether a COVID-19 vaccine it is developing is successful, and will submit it for approval immediately if that is the case.
As the race to develop a safe and effective coronavirus vaccine reaches its final stages, pharmaceutical companies have started conducting large human trials in different countries. Some countries also have signed supply deals with the companies. Below is a summary of clinical...
Nearly a fifth of 11,000 people enrolled so far in a 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer and German partner BioNTech are Black or Latino, groups among the hardest hit by the coronavirus virus pandemic, a top Pfizer executive said.
Shares of Pfizer Inc and U.S.-listed shares of partner BioNTech SE rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.
Pfizer Inc said on Friday it signed a multiyear agreement to make COVID-19 treatment remdesivir for developer Gilead Sciences Inc, which is under pressure to increase tight supplies of the antiviral drug.
Pfizer Inc said on Friday it signed a multi-year agreement with Gilead Sciences Inc to manufacture and supply the company's antiviral drug remdesivir for COVID-19 patients.
Canada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.